AIIMS Delhi to start screening children for Covaxin trials from Monday

The All India Institute of Medical Sciences (AIIMS), Delhi, will start screening children for clinical trials of indigenous home-grown Covid-19 vaccineBharat Biotech‘s Covaxin, from Monday, sources said.

AIIMS Delhi will be starting clinical trials after AIIMS Patna which started the trials recently on children aged between 12 and 18 years old.

After getting permission from the Drugs Controller General of India (DCGI), AIIMS, Delhi is now starting the screening for clinical trials before starting the trials.

To grant the permission of trials, DCGI’s approval was followed by a recommendation on May 12 by a Subject Expert Committee (SEC).

  • Related Posts

    • Pharma
    • July 22, 2025
    • 99 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    • Pharma
    • July 16, 2025
    • 489 views
    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end